share_log

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

kiniksa pharmaceuticals將在第七屆evercore ISI HealthCONx大會上進行演講
GlobeNewswire ·  11/27 05:01

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time.

倫敦,2024年11月26日(全球新聞網)-- kiniksa pharmaceuticals國際有限公司(納斯達克:KNSA)今天宣佈管理層將參加2024年12月3日上午9:35(東部時間)舉行的第七屆evercore ISI HealthCONx會議的爐邊聊天。

A live webcast of Kiniksa's presentation will be accessible through the Investors section of the company's website at . A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

kiniksa的演示將通過該公司網站的投資者部分實時網絡廣播。活動重播將在大約48小時後在kiniksa的網站上提供。

About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit .

ARCALYST是再生元製藥公司的註冊商標。
kiniksa pharmaceuticals是一家專注於發現、收購、開發和商業化治療藥物的商業階段生物製藥公司,爲患有嚴重未滿足醫療需求的患者提供治療。 kiniksa pharmaceuticals的免疫調節資產基於強大的生物學基礎或經過驗證的機制,針對一系列未得到滿足的心血管疾病和自身免疫情況,並具有差異化的潛力。欲了解更多信息,請訪問。

Every Second Counts!

時間寶貴!

Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

kiniksa投資者聯繫人
喬納森·柯珊鮑姆
(781) 829-3949
jkirshenbaum@kiniksa.com

Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com

Kiniksa媒體聯繫人
Tyler Gagnon
(擔任服務代理人的地址、郵政編碼和電話號碼,包括區域代碼)
tgagnon@kiniksa.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論